The exogenous delivery of microRNA-449b-5p using spermidine-PLGA nanoparticles efficiently decreases hepatic injury

Abstract

The present study highlights the importance of miR-449b-5p in the inhibition of HMGB1 and thereby it's treatment potential in hepatic injury.

Optimization and characterization of miRNA-129-5p-encapsulated poly (lactic-co-glycolic acid) nanoparticles to reprogram activated microglia

“…Therefore, we exclude any alternative variation with EGCG in this study. Previous studies indicate that EGCG can be an effective excipient for complexation with small interference RNA, 48,49 yet we were unable to demonstrate such benefits of EGCG for miRNA delivery. All NP formulations were fabricated using the oil-in-water double emulsion solvent evaporation method described previously.…”

“…33 The excipients were chosen based on the previously reported data of their successful use. It was demonstrated that EGCG facilitated RNA condensation by low-molecularweight polymers, 50,51 whereas Sp conjugated to PLGA 46 and PEI anchored into PLGA-based NPs helped with better incorporation of miRNA via electrostatic complexation. 33 We characterized all nanoformulations obtained in terms of their morphology, size, zeta potential, physical state and stability, composition, interaction with the aqueous phase, and miR-129 release kinetics.…”

“…[41][42][43] To overcome these obstacles, different approaches have been applied including utilizing various polymer molecular weights, the ratio of lactic acid to glycolic acid in the copolymers, and PLGA concentration and the volume ratio (water/oil phases), or incorporation of cationic excipients admixing to RNA or cationic excipient conjugation with PLGA. 34,[44][45][46] The primary goal of this study was to improve existing approaches of miRNA encapsulation to develop a clinically viable strategy that achieves an effective and sustained release of miRNA with a favorable risk-benet ratio to limit immune responses for immunomodulation. In particular, aside from miRNA protection by PLGA-based polymer vehicle, we expect to get synergistic anti-inammatory therapeutic effects using miR-129 and PLGA-based NPs together.…”

Ischemia Reperfusion Injury: Opportunities for Nanoparticles

“…Pioglitazone–PLGA NPs were predominantly present in monocytes and macrophages and ameliorated cardiac remodeling through impairing the recruitment and M2 polarization of macrophages after intravenous injection . In addition to small molecular drugs, Hu et al developed miR-449b-5p-incorporated PLGA NPs, which promoted hepatic cells’ survival and decreased their apoptosis through pNF-kB and p-65 inactivation …”

“…69 In addition to small molecular drugs, Hu et al developed miR-449b-5p-incorporated PLGA NPs, which promoted hepatic cells' survival and decreased their apoptosis through pNF-kB and p-65 inactivation. 70 Physical properties may influence the biodistribution of PLGA NP in vivo. Therefore, a comparative study was performed to investigate the passive targeting ability of PLGA NPs with different particle sizes.…”